Nivudirsen (BMN 351)

RNA / oligonucleotide

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Duchenne Muscular Dystrophy
NCT07573631 · BioMarin Pharmaceutical
2026-04-20 – 2031-12 · Duchenne Muscular Dystrophy (DMD)
What this study did
Phase 1/2 (1)
Duchenne Muscular Dystrophy

Competitive landscape

This drug's own stage for Duchenne Muscular Dystrophy: Phase 1/2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Nivudirsen (BMN 351): this drugPhase 1/2RNA / oligonucleotideDMD exon 51not yet gradedNo reviewed efficacy summary in this indication
GivinostatApprovedSmall moleculeHDACReliable signal
NCT02851797: Mean Change From Baseline in 4 Standard Stairs (4SC) Climb After 18 Months of Treatment (Baseline and 18 months): Givinostat 1.27 seconds (Standard Error 0.04) | Placebo 1.48 seconds (Standard Error 0.058)
DeramiocelPhase 3Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
RGX-202Phase 2/3Gene therapy / editingDystrophin (microdystrophin transgene)not yet gradedNo reviewed efficacy summary in this indication
Delpacibart ZotadirsenPhase 2RNA / oligonucleotideDMD exon 44not yet gradedNo reviewed efficacy summary in this indication
BampidirsenPhase 1/2RNA / oligonucleotideDMD exon 53not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Nivudirsen (BMN 351) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
April 2027 (1)
Phase 1/2Duchenne Muscular DystrophyActive not recruiting
Est. primary completion 2027-04-14 · NCT06280209 · CT.gov ↗
What to watch
2031 (1)
December 2031 (1)
Phase 2Duchenne Muscular DystrophyEnrolling by invitation
Est. primary completion 2031-12 · NCT07573631 · CT.gov ↗
What to watch

See the full readout calendar ↗